Evidence map›Paper›PMID 31758421›Full record

ArticleClinical rheumatology2020

Late-onset systemic lupus erythematosus: characteristics and outcome in comparison to juvenile- and adult-onset patients-a multicenter retrospective cohort.

Basma M Medhat, Mervat Essam Behiry, Nesreen Sobhy, Yomna Farag, Huda Marzouk, Noha Mostafa, Iman Khalifa, Marwa Elkhalifa, Basma M Eissa, Eman Hassan ElSayed Hassan

Abstract readComparative StudyMulticenter Study
PubMed Publisher
In one paragraph

Article in Clinical rheumatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Systemic lupus erythematosus as a genetic disease.Clinical immunology (Orlando, Fla.) · 2022
    Article
  9. Review
  10. Article
  11. Article
  12. Frontiers in microbiology · 2022
    Article
  13. Review
  14. Article
  15. Polymyalgia Rheumatica or Late Onset Lupus? A Case Report.Journal of investigative medicine high impact case reports
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Basma M MedhatRheumatology and Rehabilitation Department, Faculty of Medicine, Cairo University, Kasr Al Ainy St., Cairo, 11562, Egypt. basmamedhat@kasralainy.edu.eg.ORCID http://orcid.org/0000-0001-6944-6367
Mervat Essam BehiryInternal Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
Nesreen SobhyRheumatology and Rehabilitation Department, Faculty of Medicine, Cairo University, Kasr Al Ainy St., Cairo, 11562, Egypt.
Yomna FaragPediatric Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
Huda MarzoukPediatric Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
Noha MostafaPediatric Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
Iman KhalifaPediatric Department, Faculty of Medicine, Helwan University, Helwan, Egypt.
Marwa ElkhalifaRheumatology Unit, Internal Medicine Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Basma M EissaRheumatology and Rehabilitation Department, Faculty of Medicine, Cairo University, Kasr Al Ainy St., Cairo, 11562, Egypt.
Eman Hassan ElSayed HassanRheumatology Unit, Internal Medicine Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe aim of this study was to investigate the characteristics and outcome of systemic lupus erythematosus (SLE) among elderly-onset patients.

methodsThis study included 575 SLE patients managed at Cairo, Alexandria, and Helwan universities from August 2014 to 2018: of whom 49 (8.5%), 420 (73%), and 106 (18.4%) were elderly- (> 50 years), adult- (17-50 years), and juvenile- (≤ 16 years) onset patients, respectively. Cumulative characteristics were recorded. Disease activity at the last visit was investigated through the Systemic Lupus Erythematosus Disease Activity Index-2K (SLEDAI-2K), whereby lupus low disease activity (LLDA) was defined as a SLEDAI-2K score ≤ 4. The disease outcome was assessed through investigating disease damage (Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI)) and the prevalence of mortality. Quantitative and categorical data were compared using Kruskal-Wallis and Mann-Whitney tests, and chi-square (χ

resultsLate-onset SLE (LSLE) patients demonstrated the lowest prevalence of constitutional and mucocutaneous manifestations (p < 0.001), serositis (p = 0.006), nephritis (p < 0.001), neuropsychiatric involvement (p < 0.001), and hypocomplementinemia (p < 0.001), but showed the highest prevalence of comorbidities and multimorbidity (comorbidities ≥ 2) (p < 0.001), and positive anti-ds DNA antibodies (p < 0.001). Elderly-onset patients demonstrated the lowest SLEDAI-2K and SDI scores, achieved LLDA the most (p < 0.001), and developed any damage (SDI ≥ 1) the least (p < 0.001). The prevalence of mortality was comparable across the three age groups (p = 0.6).

conclusionsLate-onset SLE patients (8.5%) showed the lowest prevalence of major organ involvement and the highest prevalence of comorbidities, and demonstrated more favorable disease activity and damage indices.Key Points• The disease characteristics and outcome among LSLE patients are characterized by being controversial, with studies from the Middle East being limited. Our cohort constituted of 8.5% elderly-onset SLE patients-who were characterized by the lowest prevalence of major organ involvement and the lowest activity and damage indices-making the disease pattern more favorable in this age group, despite being characterized by the highest prevalence of comorbidities.

Indexed as

AdolescentAdultAgedAge of OnsetChildComorbidityEgyptFemaleGlucocorticoidsHumansImmunosuppressive AgentsLupus Erythematosus, SystemicMaleMiddle AgedRetrospective StudiesSeverity of Illness IndexGlucocorticoidsImmunosuppressive AgentsCharacteristicsDisease outcomeElderly onsetJuvenileLate onsetSystemic lupus erythematosus

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.